Unraveling the Role of BAG3 in Hepatic Fibrosis: Genetic and Biomarker Insights in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262311286 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Benedetta Maria Motta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy. Hauptthemen laut MEDLINE: Liver Cirrhosis, Adaptor Proteins, Signal Transducing, Apoptosis Regulatory Proteins, Fatty Liver. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a major global health burden, with hepatic fibrosis being the strongest determinant of clinical outcomes. While genetic variants such as PNPLA3 and TM6SF2 are recognized drivers of disease progression, the downstream molecular mediators linking genetic susceptibility to fibrogenesis remain unclear. This study investigated the role of the stress-response co-chaperone BAG3 as a circulating biomarker of hepatic fibrosis and its association with PNPLA3 and TM6SF2 genotypes. In a well-characterized Southern European cohort of 146 MASLD patients, liver fibrosis was assessed using the FIB-4 index, serum BAG3 levels were quantified by ELISA, and genotyping for PNPLA3 and TM6SF2 variants was performed. BAG3 concentrations were significantly higher in patients with advanced disease and correlated positively with FIB-4 values. Carriers of the TM6SF2 risk allele exhibited increased BAG3 levels, and a cumulative increase was observed with multiple PNPLA3 and TM6SF2 risk alleles. These findings suggest that BAG3 may represent a potential, non-invasive biomarker reflecting fibrogenic burden and a mechanistic link between genetic risk and hepatic fibrosis in MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
- FIBROSYS s.r.l. Academic Spin-off, University of Salerno, 84081 Baronissi, Italy.
ORCID-Profile: Benedetta Maria Motta, Alessandra Rosati, Mariano Festa, Anna Basile, Marcello Persico
Zitieren
APA
Motta, B. M., Rosati, A., Festa, M., Basile, A., Sarcina, T., Turco, M. C., & Persico, M. (2025). Unraveling the Role of BAG3 in Hepatic Fibrosis: Genetic and Biomarker Insights in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311286
Vancouver
Motta BM, Rosati A, Festa M, Basile A, Sarcina T, Turco MC, et al. Unraveling the Role of BAG3 in Hepatic Fibrosis: Genetic and Biomarker Insights in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311286
BibTeX
@article{Motta2025,
author = {Motta, Benedetta Maria and Rosati, Alessandra and Festa, Mariano and Basile, Anna and Sarcina, Tommaso and Turco, Maria Caterina and Persico, Marcello},
title = {Unraveling the Role of BAG3 in Hepatic Fibrosis: Genetic and Biomarker Insights in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262311286}
}
EUVIMED